Evexia Wealth LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

Evexia Wealth LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 4.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,135 shares of the company’s stock after acquiring an additional 464 shares during the quarter. Eli Lilly and Company makes up 3.9% of Evexia Wealth LLC’s holdings, making the stock its 9th biggest position. Evexia Wealth LLC’s holdings in Eli Lilly and Company were worth $10,903,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Public Employees Retirement System of Ohio raised its stake in shares of Eli Lilly and Company by 2.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 483,445 shares of the company’s stock valued at $281,810,000 after buying an additional 11,421 shares during the period. O Dell Group LLC boosted its position in Eli Lilly and Company by 2.0% during the fourth quarter. O Dell Group LLC now owns 884 shares of the company’s stock worth $516,000 after purchasing an additional 17 shares during the period. Optimist Retirement Group LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $2,511,000. PCA Investment Advisory Services Inc. raised its position in shares of Eli Lilly and Company by 7.4% in the fourth quarter. PCA Investment Advisory Services Inc. now owns 1,006 shares of the company’s stock valued at $586,000 after purchasing an additional 69 shares during the period. Finally, Oarsman Capital Inc. lifted its stake in shares of Eli Lilly and Company by 39.5% during the 4th quarter. Oarsman Capital Inc. now owns 2,587 shares of the company’s stock valued at $1,508,000 after buying an additional 732 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 2.3 %

Shares of LLY stock traded up $21.37 during mid-day trading on Friday, reaching $932.06. The stock had a trading volume of 2,293,874 shares, compared to its average volume of 3,009,544. The firm has a market capitalization of $885.83 billion, a PE ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The stock’s 50-day moving average price is $910.84 and its two-hundred day moving average price is $852.32. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Citigroup started coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target for the company. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $979.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.